Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May 24:4:234-242.
doi: 10.1016/j.trci.2018.04.003. eCollection 2018.

Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials

Michael Gold  1 , Joan Amatniek  2 , Maria C Carrillo  3 , Jesse M Cedarbaum  4 , James A Hendrix  3 , Bradley B Miller  5 , Julie M Robillard  6 , J Jeremy Rice  7 , Holly Soares  1 , Maria B Tome  8 , Ioannis Tarnanas  9   10   11   12 , Gabriel Vargas  13 , Lisa J Bain  14 , Sara J Czaja  15
Affiliations
Review

Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials

Michael Gold et al. Alzheimers Dement (N Y). .

Abstract

Digital technology is transforming the development of drugs for Alzheimer's disease and was the topic of the Alzheimer's Association's Research Roundtable on its May 23-24, 2017 meeting. Research indicates that wearable devices and unobtrusive passive sensors that enable the collection of frequent or continuous, objective, and multidimensional data during daily activities may capture subtle changes in cognition and functional capacity long before the onset of dementia. The potential to exploit these technologies to improve clinical trials as both recruitment and retention tools as well as for potential end points was discussed. The implications for the collection and use of large amounts of data, lessons learned from other related disease areas, ethical concerns raised by these new technologies, and regulatory issues were also covered in the meeting. Finally, the challenges and opportunities of these new technologies for future use were discussed.

Keywords: Alzheimer's disease; Biomarkers; Clinical trials; Cognition; Digital technology; Function.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dorsey E.R., Venuto C., Venkataraman V., Harris D.A., Kieburtz K. Novel methods and technologies for 21st-century clinical trials: A review. JAMA Neurol. 2015;72:582–588. - PMC - PubMed
    1. Wild K.V., Mattek N., Austin D., Kaye J.A. “Are You Sure?”: lapses in self-reported activities among healthy older adults reporting online. J Appl Gerontol. 2016;35:627–641. - PMC - PubMed
    1. Redfield M.M., Anstrom K.J., Levine J.A., Koepp G.A., Borlaug B.A., Chen H.H. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med. 2015;373:2314–2324. - PMC - PubMed
    1. Kirste T., Hoffmeyer A., Koldrack P., Bauer A., Schubert S., Schroder S. Detecting the effect of Alzheimer's disease on everyday motion behavior. J Alzheimers Dis. 2014;38:121–132. - PubMed
    1. Dodge H.H., Mattek N.C., Austin D., Hayes T.L., Kaye J.A. In-home walking speeds and variability trajectories associated with mild cognitive impairment. Neurology. 2012;78:1946–1952. - PMC - PubMed